BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23865864)

  • 21. CYP2J2*7 single nucleotide polymorphism in a Chinese population.
    Wang H; Jiang Y; Liu Y; Lin C; Cheng G; Chen X; Hao B; Tan W; Lin D; He F
    Clin Chim Acta; 2006 Mar; 365(1-2):125-8. PubMed ID: 16182271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
    Lu J; Liu D; Zhou X; Chen A; Jiang Z; Ye X; Liu M; Wang X
    Phytomedicine; 2018 Jan; 39():137-145. PubMed ID: 29433675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.
    Chen C; Wei X; Rao X; Wu J; Yang S; Chen F; Ma D; Zhou J; Dackor RT; Zeldin DC; Wang DW
    J Pharmacol Exp Ther; 2011 Feb; 336(2):344-55. PubMed ID: 21030485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
    Zordoky BN; El-Kadi AO
    Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2J2
    Tao P; Jiang Y; Wang H; Gao G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):932-941. PubMed ID: 34707002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2.
    Lee AC; Murray M
    Mol Pharmacol; 2010 Jun; 77(6):987-94. PubMed ID: 20194533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research progress of human cytochrome P450 2J2 and its ligands].
    Ma HY; Ning J; Ge GB; Yang L; Hao DC
    Yao Xue Xue Bao; 2017 Jan; 52(1):26-33. PubMed ID: 29911373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα
    He Z; Yang Y; Wen Z; Chen C; Xu X; Zhu Y; Wang Y; Wang DW
    J Lipid Res; 2017 Jul; 58(7):1338-1353. PubMed ID: 28554983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history.
    Wang CP; Hung WC; Yu TH; Chiu CA; Lu LF; Chung FM; Hung CH; Shin SJ; Chen HJ; Lee YJ
    Exp Clin Endocrinol Diabetes; 2010 Jun; 118(6):346-52. PubMed ID: 20140850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
    Leow JWH; Chan ECY
    Pharmacol Ther; 2024 Jun; 258():108637. PubMed ID: 38521247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis.
    Zhao G; Tu L; Li X; Yang S; Chen C; Xu X; Wang P; Wang DW
    Hum Gene Ther; 2012 Jul; 23(7):688-99. PubMed ID: 22260463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy.
    Chen C; Wang DW
    Curr Top Med Chem; 2013; 13(12):1454-69. PubMed ID: 23688135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome P450-CYP2 Family-Epoxygenase Role in Inflammation and Cancer.
    Chen C; Wang DW
    Adv Pharmacol; 2015; 74():193-221. PubMed ID: 26233908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of the epoxygenase CYP2J2 in the endothelium.
    Askari A; Thomson SJ; Edin ML; Zeldin DC; Bishop-Bailey D
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():56-63. PubMed ID: 23474289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.
    Karkhanis A; Hong Y; Chan ECY
    Biochem Pharmacol; 2017 Jul; 135():12-21. PubMed ID: 28237650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2.
    Kojima A; Nadai M; Murayama N; Yamazaki H; Katoh M
    Xenobiotica; 2022 Jul; 52(7):669-675. PubMed ID: 36251932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
    Leow JWH; Gu Y; Chan ECY
    Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform.
    Lee B; Wu Z; Sung SH; Lee T; Song KS; Lee MY; Liu KH
    Food Chem Toxicol; 2014 Aug; 70():94-9. PubMed ID: 24788058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.
    Arnold WR; Baylon JL; Tajkhorshid E; Das A
    Biochemistry; 2017 Dec; 56(51):6700-6712. PubMed ID: 29200270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
    Evangelista EA; Kaspera R; Mokadam NA; Jones JP; Totah RA
    Drug Metab Dispos; 2013 Dec; 41(12):2087-94. PubMed ID: 24021950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.